Got $1,000? Here's a Dirt-Cheap Big Pharma Stock to Buy
As COVID-19 was labeled a global pandemic by the World Health Organization in March 2020, many pharma companies began their research aimed at introducing lifesaving vaccines and treatments to combat the disease.
No company was arguably more critical to this mission than the pharma stock Pfizer (NYSE: PFE), which introduced the first-to-market COVID-19 vaccine -- alongside its German partner BioNTech (NASDAQ: BNTX) -- called Comirnaty. And more recently, Pfizer has brought to market its anti-viral COVID-19 pill known as Paxlovid.
Without even considering its leadership on the COVID-19 front, I believe Pfizer is an excellent pick for both value investors and income investors who find themselves with $1,000 available to invest. Let's take a closer look at four reasons why.
Source Fool.com
